162 related articles for article (PubMed ID: 31219000)
1. In Situ Cellular Response Underlying Successful Treatment of Mucosal Leishmaniasis with a Combination of Pentavalent Antimonial and Pentoxifylline.
Faria DR; Barbieri LC; Koh CC; Machado PRL; Barreto CC; Lima CMF; Lessa MM; Carvalho E; Gollob KJ; Dutra WO
Am J Trop Med Hyg; 2019 Aug; 101(2):392-401. PubMed ID: 31219000
[TBL] [Abstract][Full Text] [Related]
2. Oral Pentoxifylline Associated with Pentavalent Antimony: A Randomized Trial for Cutaneous Leishmaniasis.
Brito G; Dourado M; Guimarães LH; Meireles E; Schriefer A; de Carvalho EM; Machado PRL
Am J Trop Med Hyg; 2017 May; 96(5):1155-1159. PubMed ID: 28500815
[TBL] [Abstract][Full Text] [Related]
3. Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis.
Machado PR; Lessa H; Lessa M; Guimarães LH; Bang H; Ho JL; Carvalho EM
Clin Infect Dis; 2007 Mar; 44(6):788-93. PubMed ID: 17304449
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony.
Lessa HA; Machado P; Lima F; Cruz AA; Bacellar O; Guerreiro J; Carvalho EM
Am J Trop Med Hyg; 2001 Aug; 65(2):87-9. PubMed ID: 11508396
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of miltefosine monotherapy and pentoxifylline associated with pentavalent antimony in treating mucosal leishmaniasis.
Ventin F; Cincurá C; Machado PRL
Expert Rev Anti Infect Ther; 2018 Mar; 16(3):219-225. PubMed ID: 29411659
[TBL] [Abstract][Full Text] [Related]
6. Pentoxifylline prevents the meglumine antimonate-induced renal toxicity in rats, but not that induced by the inorganic antimony pentachloride.
de Moura FJ; Leal PP; de Souza Furtado R; Muniz-Junqueira MI; Veiga JP
Toxicology; 2008 Jan; 243(1-2):66-74. PubMed ID: 18022309
[TBL] [Abstract][Full Text] [Related]
7. Clinical and immunological outcome in cutaneous leishmaniasis patients treated with pentoxifylline.
Brito G; Dourado M; Polari L; Celestino D; Carvalho LP; Queiroz A; Carvalho EM; Machado PR; Passos S
Am J Trop Med Hyg; 2014 Apr; 90(4):617-20. PubMed ID: 24567316
[TBL] [Abstract][Full Text] [Related]
8. Immunological determinants of clinical outcome in Peruvian patients with tegumentary leishmaniasis treated with pentavalent antimonials.
Maurer-Cecchini A; Decuypere S; Chappuis F; Alexandrenne C; De Doncker S; Boelaert M; Dujardin JC; Loutan L; Dayer JM; Tulliano G; Arevalo J; Llanos-Cuentas A; Chizzolini C
Infect Immun; 2009 May; 77(5):2022-9. PubMed ID: 19237520
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory effect of pentoxifylline during human allograft rejection: involvement of tumor necrosis factor-alpha and adhesion molecules.
Noel C; Copin MC; Hazzan M; Labalette M; Susen S; Lelievre G; Dessaint JP
Transplantation; 2000 Mar; 69(6):1102-7. PubMed ID: 10762214
[TBL] [Abstract][Full Text] [Related]
10. Mucosal leishmaniasis: in situ characterization of the host inflammatory response, before and after treatment.
Amato VS; de Andrade HF; Duarte MI
Acta Trop; 2003 Jan; 85(1):39-49. PubMed ID: 12505182
[TBL] [Abstract][Full Text] [Related]
11. Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis.
Sadeghian G; Nilforoushzadeh MA
Int J Dermatol; 2006 Jul; 45(7):819-21. PubMed ID: 16863518
[TBL] [Abstract][Full Text] [Related]
12. A Pilot Randomized Clinical Trial: Oral Miltefosine and Pentavalent Antimonials Associated With Pentoxifylline for the Treatment of American Tegumentary Leishmaniasis.
Martins SS; Barroso DH; Rodrigues BC; da Motta JOC; Freire GSM; Pereira LIA; Kurisky PS; Gomes CM; Sampaio RNR
Front Cell Infect Microbiol; 2021; 11():700323. PubMed ID: 34277476
[TBL] [Abstract][Full Text] [Related]
13. Oral pentoxifylline and pentavalent antimony for treatment of leishmaniasis: promising but inconclusive evidence of superiority, compared with antimony monotherapy.
Ojha RP; Cervantes D; Fischbach LA
Clin Infect Dis; 2007 Oct; 45(8):1104; author reply 1005-6. PubMed ID: 17879933
[No Abstract] [Full Text] [Related]
14. [The evaluation of the tolerance and nephrotoxicity of pentavalent antimony administered in a dose of 40 mg Sb V/kg/day, 12/12 hr, for 30 days in the mucocutaneous form of leishmaniasis].
Sampaio RN; de Paula CD; Sampaio JH; Furtado Rde S; Leal PP; Rosa TT; Rodrigues ME; Veiga JP
Rev Soc Bras Med Trop; 1997; 30(6):457-63. PubMed ID: 9463192
[TBL] [Abstract][Full Text] [Related]
15. Short report: persistence of tumor necrosis factor-alpha in situ after lesion healing in mucosal leishmaniasis.
Amato VS; Andrade HF; Amato Neto V; Duarte MI
Am J Trop Med Hyg; 2003 May; 68(5):527-8. PubMed ID: 12812337
[TBL] [Abstract][Full Text] [Related]
16. American cutaneous leishmaniasis unresponsive to antimonial drugs: successful treatment using combination of N-methilglucamine antimoniate plus pentoxifylline.
Báfica A; Oliveira F; Freitas LA; Nascimento EG; Barral A
Int J Dermatol; 2003 Mar; 42(3):203-7. PubMed ID: 12653916
[TBL] [Abstract][Full Text] [Related]
17. Drug resistance in Indian visceral leishmaniasis.
Sundar S
Trop Med Int Health; 2001 Nov; 6(11):849-54. PubMed ID: 11703838
[TBL] [Abstract][Full Text] [Related]
18. [Renal function in patients with mucocutaneous leishmaniasis treated with pentavalent antimony compounds].
Veiga JP; Rosa TT; Kimachi T; Wolff ER; Sampaio RN; Gagliardi AR; Junqueira Júnior LF; Costa JM; Marsden PD
Rev Inst Med Trop Sao Paulo; 1985; 27(6):298-302. PubMed ID: 3014634
[No Abstract] [Full Text] [Related]
19. Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis.
Faria DR; Gollob KJ; Barbosa J; Schriefer A; Machado PR; Lessa H; Carvalho LP; Romano-Silva MA; de Jesus AR; Carvalho EM; Dutra WO
Infect Immun; 2005 Dec; 73(12):7853-9. PubMed ID: 16299275
[TBL] [Abstract][Full Text] [Related]
20. Overcoming TNF-alpha and drug resistance of human renal cell carcinoma cells by treatment with pentoxifylline in combination with TNF-alpha or drugs: the role of TNF-alpha mRNA downregulation in tumor cell sensitization.
Mizutani Y; Bonavida B; Nio Y; Yoshida O
J Urol; 1994 Jun; 151(6):1697-702. PubMed ID: 8189599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
